Primaveris

Primaveris Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative therapies for women's health, with a primary focus on menopause-related conditions. The company's lead program is a non-hormonal, small molecule neurokinin 3 receptor (NK3R) antagonist designed to treat vasomotor symptoms such as hot flashes and night sweats. By targeting the underlying neurological pathways of thermoregulation, Primaveris aims to provide a safe and effective alternative to hormone replacement therapy. The leadership team consists of industry veterans from Wyeth and Pfizer with extensive experience in reproductive endocrinology and drug development. The company is headquartered in Berwyn, Pennsylvania, and operates as a private entity.